Karyopharm Q2 net loss $37.3M; explores financing/strategic alternatives; cash $52M

Karyopharm Therapeutics Inc.

2025-Q2 EPS reported -$7.11 vs consensus -$4.18 ▼ miss (-70.1%)

Total revenue $37.9M; US XPOVIO net product revenue $29.7M (+6% YoY). Net loss $37.3M ($4.32/share).
FY2025 total revenue guidance reaffirmed $140-155M; US XPOVIO revenue guidance updated to $110-120M.
Cash, equivalents & investments $52M at June 30; expects liquidity to fund ops into Jan 2026 excluding $24.5M note maturity Oct 2025.
Phase 3 SENTRY (myelofibrosis) enrollment screening close this week; top-line data expected March 2026.
Engaged Centerview Partners to explore financing and strategic alternatives to extend cash runway and maximize value.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.